ABSTRACT. Background and Objective. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is frequently associated with neonatal hyperbilirubinemia, which in severe cases may cause kernicterus and death. Because G-6-PD-deficient individuals frequently undergo acute, trigger-induced hemolytic episodes, increased hemolysis has frequently been implied in the pathogenesis of this neonatal hyperbilirubinemia. However, in Sephardic Jewish G-6-PD-deficient neonates, the rate of hemolysis, reflected by blood carboxyhemoglobin values corrected for inspired carbon monoxide, has been shown to be elevated, not only in those who developed hyperbilirubinemia, but also, to a similar extent, in those who remained only moderately jaundiced. Because at any point, serum total bilirubin values reflect a balance between bilirubin production on the one hand and bilirubin conjugation and elimination on the other, we suspected bilirubin conjugation to be a key factor in the pathogenesis of the hyperbilirubinemia. Physiologically, a fraction of conjugated bilirubin refluxes from the hepatocyte to the serum, and accurate determination of serum conjugated bilirubin fractions can be used to mirror intrahepatocytic bilirubin. Using this principle, we previously demonstrated a decreased diconjugated bilirubin fraction in hyperbilirubinemic G-6-PD-deficient neonates compared with hyperbilirubinemic G-6-PDnormal controls, suggesting diminished bilirubin conjugation. This conjugated bilirubin pattern probably reflects the recently described interaction between G-6-PD deficiency and the variant promoter for the gene encoding the bilirubin conjugating enzyme UDP glucuronosyltransferase, as seen in Gilbert's syndrome. Therefore, we postulated that efficiency of bilirubin conjugation is a crucial factor in the development of hyperbilirubinemia in G-6-PD-deficient neonates. We hypothesized that those G-6-PD-deficient neonates who develop hyperbilirubinemia would have decreased bilirubin conjugation ability, whereas those with a more efficient conjugating system would have a lesser degree of bilirubinemia.
serum diazo total bilirubin values ranged from 171 to 254 mol/L (10 -14.9 mg/dL). At this point, simultaneous with the diazo bilirubin determination, serum was collected and frozen for high-performance liquid chromatography (HPLC) measurement of serum bilirubin fractions. The infants were followed clinically and with serum diazo bilirubin determinations until they either did not exceed a serum diazo bilirubin value of 254 mol/L (14.9 mg/dL) (nonhyperbilirubinemic) or until bilirubin values rose above this level (hyperbilirubinemic), by a process of self-selection. A method of alkaline methanolysis, followed by reverse-phase HPLC, was used to measure unconjugated bilirubin and the mono-and diconjugated fractions of serum conjugated bilirubin. Total HPLC bilirubin and total conjugated bilirubin values were calculated from these measured bilirubin fractions. Patients also were classified according to the serum total conjugated bilirubin value as low bilirubin conjugators (serum total conjugated bilirubin less than median) or as high bilirubin conjugators (serum total conjugated bilirubin greater than median). The data were analyzed by comparing serum conjugated bilirubin fractions between the hyperbilirubinemic and nonhyperbilirubinemic groups and the risk of developing hyperbilirubinemia in the low bilirubin conjugators, relative to that of the high bilirubin conjugators.
Results. Neonates were sampled at 53 ؎ 12 and 58 ؎ 12 hours for the subsequently hyperbilirubinemic and nonhyperbilirubinemic groups, respectively (NS) 06 -3.36) .
Conclusions. Although serum total bilirubin levels at the time of sampling were virtually identical, those neonates who subsequently developed hyperbilirubinemia had significantly lower serum conjugated bilirubin fractions than those who remained within the nonhyperbilirubinemic range. The diconjugated bilirubin fraction was especially affected. Those infants with serum total conjugated bilirubin fraction less than the median had a greater risk of developing hyperbilirubinemia than those with greater than the median. These findings reflect inefficient bilirubin conjugation ability in G-6-PD-deficient neonates who develop hyperbilirubinemia. We believe that the current findings are the functional manifestation of the interaction previously reported between G-6-PD deficiency and the variant gene promoter, as seen in Gilbert's syndrome. Diminished bilirubin conjugation ability appears to be a determining factor in the pathogenesis of G-6-PD deficiency associated neonatal hyperbilirubinemia. Pediatrics 1998;102(3). URL: http:// www.pediatrics.org/cgi/content/full/102/3/e37; glucose-6-phosphate dehydrogenase deficiency, neonatal hyperbilirubinemia, bilirubin, bilirubin conjugation, serum conjugated bilirubin, monoglucuronide, diglucuronide, high-performance liquid chromatography, Sephardic Jews.
ABBREVIATIONS. G-6-PD, glucose-6-phosphate dehydrogenase; HPLC, high-performance liquid chromatography; CI, confidence interval. G lucose-6-phosphate dehydrogenase (G-6-PD) deficiency is associated with a high incidence of neonatal hyperbilirubinemia 1,2 that may, in severe cases, cause kernicterus and death. [3] [4] [5] Because of the association between G-6-PD deficiency and acute, drug-induced hemolytic episodes, acute hemolysis has been implicated frequently in the pathogenesis of the hyperbilirubinemia. However, the associated jaundice appears even when all known triggers of hemolysis are avoided. 6 Using carboxyhemoglobin measurements corrected for inspired carbon monoxide as an accurate index of bilirubin production, it was found that bilirubin production in G-6-PD-deficient neonates was increased to a similar extent not only in those who developed hyperbilirubinemia, but also in those who did not. 7 Because at any point, serum bilirubin levels reflect a balance between bilirubin production on the one hand and bilirubin conjugation and elimination on the other, we proposed that decreased bilirubin conjugation would be crucial to the pathogenesis of excessive jaundice in G-6-PD-deficient neonates. Physiologically, a fraction of conjugated bilirubin refluxes from the hepatocyte to the serum, and accurate determination of serum conjugated bilirubin fractions can be used to mirror intrahepatocytic bilirubin. 8, 9 Using this principle, we have demonstrated previously a decreased serum diconjugated bilirubin fraction, reflective of diminished bilirubin-conjugating ability in hyperbilirubinemic G-6-PD-deficient neonates, compared with hyperbilirubinemic G-6-PD normal controls. 10 This decreased bilirubin conjugation may be the functional manifestation of the recently described gene interaction between G-6-PD deficiency and the variant promoter for the gene encoding the bilirubin-conjugating enzyme UDP glucuronosyltransferase 1, as seen in Gilbert's syndrome. 11 In the current study, we assessed bilirubin conjugation by analyzing unconjugated and conjugated bilirubin fractions in serum sampled from G-6-PDdeficient neonates while they were still moderately jaundiced with serum bilirubin values in a fixed range. After sampling, the patients either developed hyperbilirubinemia (serum total diazo bilirubin Ն256 mol/L [15 mg/dL]) or remained in the nonhyperbilirubinemic range (serum total diazo bilirubin Ͻ256 mol/L [15 mg/dL]) by a natural selection process. This study design enabled us to compare conjugated bilirubin fractions from sera with similar total bilirubin values in neonates in the two groups. In addition, we determined the risk of developing hyperbilirubinemia in G-6-PD-deficient neonates with lower, versus higher, bilirubin-conjugating capacity, as determined by serum total conjugated bilirubin lesser or greater than median, respectively.
METHODS

Clinical Material
Routine Management
At the Shaare Zedek Medical Center, a subgroup of infants born to mothers of Sephardic-Jewish descent, whose families immigrated from Asia Minor, and who thus were at high risk for G-6-PD deficiency 12, 13 and its associated hyperbilirubinemia, 6 was screened for the enzyme deficiency on the first day of life. G-6-PD-deficient neonates were hospitalized routinely for observation for a minimum of 72 hours after birth, with serum total bilirubin determinations performed as clinically indicated. Discharge was delayed if total serum bilirubin values were rising and approaching criteria for phototherapy (below). Discharged newborns were followed by our staff, using our laboratory facilities, as outpatients, until it was clear that serum bilirubin values had stabilized. The compliance rate in our population was excellent, and we were confidant that we were aware of virtually all neonates who develop excessive bilirubinemia. Nursery protocol included the institution of phototherapy as part of hospitalization in G-6-PDdeficient term neonates if the serum total bilirubin value was Ͼ256 mol/L (15.0 mg/dL) in the first week of life. Exchange transfusion was performed if these values rose to Ͼ342 mol/L (20mg/ dL) and if infants were unresponsive to phototherapy.
Study Protocol
The study protocol was approved by the Shaare Zedek Medical Center's institutional review board. Candidates for the study, chosen arbitrarily from the G-6-PD-deficient population, included otherwise healthy, term, male newborns, free of any other identifiable factor known to exacerbate jaundice such as cephalhematoma, maternal diabetes, Coombs' positive hemolytic anemia, or sepsis. Infants were managed according to the routine protocol. When an infant who met criteria for entry into the study was estimated by clinical judgment to have a rising serum total bilirubin value ranging from 171 to 254 mol/L (10.0 -14.9 mg/dL), serum for high-performance liquid chromatography (HPLC) analysis of bilirubin fractions of infants was obtained along with routine total diazo bilirubin serum. Neonates were entered into the study only if their serum diazo bilirubin value was found to be 171 to 254 mol/L (10.0 -14.9 mg/dL). If the serum diazo bilirubin value was lower than the range for inclusion in the study, that infant was allowed to be included at a later time should he meet the criteria using a new serum HPLC sample, obtained with a later serum diazo bilirubin sample. Serum for the diazo and HPLC bilirubin determinations were sampled concurrently in all cases. The subsequent management of enrolled newborns was identical to that for the routine clinical protocol. The infants were followed until they either did not exceed a serum bilirubin value of 254 mol/L (14.9 mg/dL) or until the bilirubin levels rose above this level, by a process of self selection. The maximal recorded serum total bilirubin value was noted, and other routine data were recorded.
To prevent selection bias, once an infant had been sampled for the study, the only reason for subsequent exclusion was a serum total diazo bilirubin value out of the range for inclusion in the study at the time of sampling. In no instance was a neonate included or excluded based on his subsequent maximal serum total bilirubin value. No attempt was made to study a cohort and analyze serum samples on every appropriate infant because of the vast number of minimally jaundiced neonates that would have been encountered and because of the technical difficulties involved in processing so many samples.
After blood sampling, serum was separated immediately, stored at Ϫ70°C, and transported to the University of Padua in a frozen state. Laboratory methods included:
1. blood G-6-PD determinations, in which screening was performed using a qualitative color reduction method (Kit No. 400K, Sigma Diagnostics, St Louis, MO) to identify male neonates with G-6-PD deficiency, 14 and confirmed by a quantitative enzyme assay (Kit No. 345-UV, Sigma Diagnostics). The upper limit of enzyme activity for inclusion as G-6-PD-deficient was 111 U/10 12 erythrocytes according to standards determined recently for this test kit in neonates 15 ; 2. serum total bilirubin level measurements, which were determined routinely with an automated analyzer (Astra 8, Beckman Instruments, Brea, CA) using a modified diazo reaction. The system was calibrated daily using a commercial standard (Liquichek Pediatric Control, Levels 1 and 2, Bio-Rad Laboratories, Anaheim, CA); and 3. serum bilirubin conjugate determinations with tests involving alkaline methanolysis, by which bilirubin mono-and disugar conjugates were converted to the corresponding mono-and dimethyl esters in alkaline methanol. These methyl ester derivatives, along with unconjugated bilirubin, which is not affected by the transesterification reaction, were extracted into chloroform. The pigments then were separated, and the unconjugated, monoconjugated, and diconjugated bilirubin fractions quantified individually by reverse-phase HPLC. 16 Analysis of the conjugated bilirubin was performed by the method of Muraca and Blanckaert. 17 In brief, 20 mg of sodium ascorbate and 1 to 2 mg of disodium-ethylenediaminetetra-acetate were mixed with 0.2 mL of serum. A 2 mL aliquot of internal standard solution in methanol (100 g/100 mL) was then added, and the mixture treated with 2 mL of 2% (weight/volume) KOH in methanol and then vortex-mixed. After 60 to 90 seconds at 20Ϫ25°C, 2 mL of chloroform and 4 mL of glycine/HCl buffer (0.4 mL/L HCl adjusted to pH 2.4 with solid glycine) was added sequentially, and the mixture shaken and centrifuged. The organic phase was transferred to a dry tube and evaporated under nitrogen at 30°C. The residue was stored under argon at Ϫ20°C and analyzed within 1 week. Reverse-phase liquid chromatographic analysis of the pigments derived from alkaline methanolysis was then performed. The within-day coefficient of variation for this method is 5% to 8%, and that for day to day, 6% to 13%. Serum conjugated bilirubin fractions have been shown to remain stable for periods of up to 6 months when stored at Ϫ70°C. It should be noted that the more accurate HPLC method of bilirubin determination may frequently give lower total bilirubin readings than does the conventional diazo method.
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Data Analysis
Measured HPLC values for unconjugated, monoconjugated, and diconjugated bilirubin fractions were used to calculate values for total bilirubin and total conjugated bilirubin. For the purpose of the study, hyperbilirubinemia was defined as a maximal serum total bilirubin diazo level Ն256 mol/L (15.0 mg/dL) at any time during the first week of life. Those whose maximal serum total bilirubin value did not exceed 254 mol/L (14.9 mg/dL) during this time were regarded as nonhyperbilirubinemic. In addition, those with serum total conjugated bilirubin values less than the median value for this parameter were defined as low bilirubin conjugators, whereas those with serum total bilirubin values greater than the median value were defined as high bilirubin conjugators. The data were analyzed by comparing serum conjugated bilirubin fractions between the hyperbilirubinemic and nonhyperbilirubinemic groups, and the risk of developing hyperbilirubinemia in the low bilirubin conjugators, relative to that of the high bilirubin conjugators. Mean values Ϯ SD and median value (range) were calculated for parametric and nonparametric data, respectively. Continuous variables were compared using Student's t test or the Mann-Whitney rank sum test, whereas categorical variables were analyzed using 2 analysis or Fisher's exact test, as appropriate. Significance for the above tests was defined as P Ͻ .05. Relative risk and 95% confidence interval (CI) were calculated to assess the risk of the low conjugators developing hyperbilirubinemia relative to the high conjugators, the latter defined as relative risk ϭ 1. Significance for this test was achieved when the 95% CI were wholly Ͼ1 or Ͻ1.
RESULTS
The serum samples were collected between July 1994 and April 1996. A total of 48 male neonates were entered into the study, of whom 26 subsequently developed serum total diazo bilirubin values Ն256 mol/L (15.0 mg/dL) (hyperbilirubinemic) and 22 remained nonhyperbilirubinemic. There were no significant differences in the clinical characteristics of the neonates; birth weights (mean Ϯ SD) were 3066 Ϯ 470 g and 3324 Ϯ 392 g, and gestational ages 39.1 Ϯ 1.0 and 39.6 Ϯ 1.2 weeks for the hyperbilirubinemic and nonhyperbilirubinemic groups, respectively. In both groups, 77% were exclusively breastfed. Neonates were delivered vaginally in 92% and 95% of the subsequently hyperbilirubinemic and nonhyperbilirubinemic groups, respectively. Serum total diazo bilirubin values (mean Ϯ SD) at the time of sampling were almost identical (214 Ϯ 27 mol/L [12.5 Ϯ 1.6 mg/dL] and 212 Ϯ 19 mol/L [12.4 Ϯ 1.1 mg/dL] for the subsequently hyperbilirubinemic and nonhyperbilirubinemic groups, respectively), whereas the time of sampling was 53 Ϯ 12 h and 58 Ϯ 10 h, respectively (NS). Maximal serum diazo total bilirubin values in the hyperbilirubinemic group, before the onset of phototherapy, were 282 Ϯ 26 mol/L (16.5 Ϯ 1.5 mg/dL), although therapy probably did not allow the bilirubin values to reach their natural peak. Measured and calculated HPLC determined values for the major bilirubin components are displayed in Table 1 , and those for the conjugated bilirubin fractions are shown graphically in Fig 1. It should be noted that despite similarity in the total and unconjugated bilirubin values in both groups at the time of sampling, the total conjugated and its mono-and diconjugated bilirubin fractions, measured from the same serum sample as the former, were significantly lower in those neonates who subsequently developed hyperbilirubinemia than in those who remained nonhyperbilirubinemic. The diconjugated bilirubin fraction was especially affected; whereas only one neonate in the subsequently hyperbilirubinemic group had undetectable levels of monoconjugated bilirubin, 18 (69%) neonates in that group had no detectable diconjugate. In contrast to the latter, in the nonhyperbilirubinemic group, only 8 (36%) had undetectable diconjugated bilirubin levels (P Ͻ .05).
The median value for serum total conjugated bilirubin at the time of sampling for the entire patient sample was 1.06 mol/L (0.06 mg/dL). Of the 24 neonates with serum total conjugated bilirubin val-ues less than median, 17 (71%) subsequently became hyperbilirubinemic compared with 9 of 24 (37.5%) of those with serum total conjugated bilirubin values greater than median (relative risk: 1.89; 95% CI: 1.06 -3.36; P ϭ .04). Furthermore, 22 of 26 (84.6%) neonates with no detectable diconjugated bilirubin, compared with 8 of 22 (36.4%) neonates with any measurable diconjugate, developed hyperbilirubinemia (relative risk: 2.33; 95% CI: 1.31-4.14; P ϭ .002).
DISCUSSION
The results of our study show that those G-6-PDdeficient neonates who developed higher maximal serum total bilirubin values had significantly lower serum conjugated bilirubin fractions than those who remained only moderately jaundiced. Conversely, those with lower serum total conjugated bilirubin values at the time of sampling were at higher risk for the subsequent development of hyperbilirubinemia. The serum bilirubin profile demonstrated in the subsequently hyperbilirubinemic G-6-PD-deficient neonates (high total and unconjugated fraction, with low total conjugated, monoconjugated, and especially diconjugated fractions) is reminiscent of that seen in conditions of partial deficiency of the bilirubin conjugating enzyme UDP glucuronosyltransferase, such as Gilbert's Syndrome. 19 These data support functionally the concept of the gene interaction demonstrated recently between G-6-PD deficiency and the variant promoter for the gene encoding this enzyme, UDP glucuronosyltransferase. 11 The primary site of the pathogenesis of the hyperbilirubinemia therefore appears to be localized to a deficiency in bilirubin conjugation. As a result, G-6-PD-deficient neonates who become hyperbilirubinemic have bilirubin conjugation ability which is even more inefficient than that of the physiological immaturity of conjugation normally found in neonates. Those with an excessively immature bilirubin eliminating capacity are more likely to develop hyperbilirubinemia than those with a more mature ability. This mechanism may exist to a certain extent in all neonates but may be exacerbated in the G-6-PD deficiency state because of increased hemolysis and the resultant additional bilirubin load. 7 In addition, the monoglucuronide preponderance in biliary excretion that must have resulted may have in itself exacerbated the enterohepatic circulation and added to the total bilirubin pool; in vitro studies have shown that hydrolysis of monoglucuronide back to unconjugated bilirubin occurs at rates four to six times faster than for diglucuronide. 20 It is unlikely that additional stages of the bilirubin elimination process, such as bilirubin uptake by the hepatocyte, or excretion of the conjugated product into the biliary tree also are involved in the pathogenesis of the hyperbilirubinemia. Deficiency of hepatic uptake of bilirubin, possibly related to deficiency of ligandin (Y protein) 21 could lead to increased serum total bilirubin values and decreased conjugated bilirubin fractions. However, in this situation, both the mono-and the diconjugated fractions should be expected to be decreased to a similar de- gree. In fact, there was a predilection for the diconjugated bilirubin component, as evidenced by a large number of neonates having unmeasurable levels of diconjugated bilirubin. It is unlikely that decreased bilirubin excretion played a part in the pathogenesis of the jaundice, because neonates with an inefficient excretory system would be expected to have higher serum conjugated bilirubin fractions, along with higher total serum bilirubin values, than those with more efficient excretory function. In fact, in our patients, higher conjugated bilirubin fractions were related inversely to maximum total serum bilirubin values and vice versa. There was no correlation between the level of erythrocyte G-6-PD enzyme activity and the unconjugated or conjugated serum bilirubin levels. However, in G-6-PD Mediterranean, levels of the enzyme are so low that there is probably little value to this type of analysis.
It could be argued that because the time of sampling in the hyperbilirubinemic group was on average 5 hours earlier than that for the nonhyperbilirubinemic group, and that because infants who develop severe hyperbilirubinemia have a greater rate of bilirubin increment, this time factor may have affected bilirubin conjugation maturation and therefore the values of the serum conjugated bilirubin fractions. However, the difference in times of sampling between the two groups was not significant. Based on the rate of rise up to the point of sampling, the serum total bilirubin values in the hyperbilirubinemic group could be expected to rise by only 1.2 mg during the 5-hour period. Because the total conjugated bilirubin values were only ϳ0.5% of the total bilirubin in the hyperbilirubinemic group, any change in the conjugated bilirubin component over the 5-hour period would have been minimal.
Although this was not a cohort study, we believe that little bias could have entered the selection or follow-up process. The neonates were selected while their serum bilirubin values were within a fixed range and before progression into hyperbilirubinemic or nonhyperbilirubinemic subgroups. The nursery staff are extremely sensitive to the high risk for developing serious hyperbilirubinemia in these G-6-PD-deficient neonates and are liberal in ordering serum bilirubin values during both hospitalization and follow-up, rather than relying on clinical judgment. Again, because the study population was not cohorted, neither the incidence of hyperbilirubinemia nor the median total conjugated bilirubin value in this selection of neonates should be regarded as representative of this entire G-6-PD-deficient population. The lower cutoff point for serum total diazo bilirubin was 171 mol/L (10 mg/dL), because at levels lower than this, conjugated bilirubin levels may be so low as to exclude useful analysis. Because phototherapy most likely had a dampening effect on the peak serum bilirubin values in the hyperbilirubinemic neonates and prevented these values from reaching their natural peak, peak serum total bilirubin values were not used for analysis.
The upper limits of physiologic jaundice are frequently defined as serum total bilirubin value of 221 mol/L (12.9 mg/dL), 22 based on the value for the 95th percentile in the Collaborative Perinatal Project, conducted between 1959 and 1966 and encompassing 35 000 neonates. 23 However, it is unlikely that neonates with exaggerated physiologic jaundice up to a serum bilirubin value of 256 mol/L (15 mg/dL) would be at any risk for neurologic damage from bilirubin encephalopathy. For the purpose of the study, therefore, we were more conservative in defining hyperbilirubinemia and used a serum bilirubin cutoff point of Ն256 mol/L (15 mg/dL). This value is equivalent to the 97th percentile for both the Collaborative Perinatal Project 23 and a subsequent study of Ͼ2000 neonates studied in the 1980s. 24 The reverse-phase HPLC method we used is extremely sensitive and accurate for the measurement of unconjugated, monoconjugated, and diconjugated bilirubin fractions in serum. Indeed, reverse-phase HPLC determinations are regarded as the standard for bilirubin measurements. 22 It should be taken into account that the HPLC method of bilirubin determination may frequently give considerably lower total bilirubin readings than does the conventional, less accurate diazo method on the same serum sample because of the presence of a diazo positive material, distinct from bilirubin and its ester conjugates, which frequently is found in serum samples containing conjugated bilirubin. 18 In conclusion, we have shown that deficient bilirubin conjugation, reflected by serum conjugated bilirubin values, is a cardinal factor in the pathogenesis of G-6-PD deficiency associated neonatal hyperbilirubinemia. In G-6-PD-deficient neonates who conjugate bilirubin less efficiently, hyperbilirubinemia is more likely to result. In contrast, those neonates with higher neonatal bilirubin conjugation ability are less likely to develop clinically significant hyperbilirubinemia. It is unknown at present whether the previous observations related to hemolysis and bilirubin production, 7 the variant promoter for the gene encoding UDP glucuronosyltransferase, 11 or the deficient serum conjugated bilirubin fractions described above are unique to Sephardic Jews with G-6-PD Mediterranean or whether they have global implications for the hundreds of millions of people worldwide estimated to have G-6-PD deficiency.
1 Additional study of the pathophysiology of this process may lead to improved therapeutic or prophylactic interventions in the clinical management of G-6-PD deficiency associated neonatal hyperbilirubinemia.
